Vasoactive intestinal peptide (VIP) had therapeutic and prophylactic effects in TNBS-induced colitis, which was related to the down-regulation role of the IFN-γ level in splenic and lamina propria CD4+ T cells (33). The gene discussed is IFNG; the disease is colitis.